Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ProQR Therapeutics 2020
Volgen
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present and discuss results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) on March 24, 2021. The data will be announced in a press release and management will host an investor conference call at 8:15 a.m. EDT the same day to discuss the results
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials LEIDEN, Netherlands & CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of vision that moved in concordance, including visual acuity, visual fields, and optical coherence tomography (OCT) retinal imaging, after a single dose. QR-421a was observed to be well tolerated with no serious adverse events reported. Based on these findings, the Company plans to advance QR-421a to two parallel pivotal Phase 2/3 trials by year end 2021 – one in early-moderate patients, one in advanced patients. Continue reading this press release Or find all press releases here.
BPPP schreef op 24 maart 2021 14:25 :
voorbeurs +12%
Tijdens beurs: +34,5%
En zag zo even de + 63%, toch te vroeg mijn winst genomen maar "achteraf" kijkt men een koe in zijn kont is een gezegde....
Als ik Yahoo Finance goed begrijp, is ieder aandeel PRQR vandaag (tot nu) gemiddeld zo'n 2,5 maal verhandeld. Dus het zal wel volatiel blijven de komende tijd.
Feest in de portefeuille vandaag!
Verhandeld volume is niet normaal. Waarom gisteren dan niet gestegen na nieuwsbericht?
Al nederlandse website tegen gekomen gefeliciteerd met stijging vandaag
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual terms of the offering. Continue reading this press release Or find all press releases here.
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering are expected to be approximately $90 million, assuming no exercise of the underwriters’ option to purchase additional shares.
@Missolapola Je weet dat er ook een ProQR 2021 discussie is ?
Ron Kerstens schreef op 31 maart 2021 10:30 :
@Missolapola Je weet dat er ook een ProQR 2021 discussie is ?
Oei, dat wist ik niet Ron. Bedankt om er mij op te attenderen, ik ga er direct naar kijken
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee